LEO Pharma and the Parker Institute Partner to Advance Skin Disease Research
- LEO Pharma and the Parker Institute have entered a 3-year partnership with the objective to advance dermatology research.
- The collaboration will leverage the Parker Institute’s expertise in trial design, artificial intelligence, and SingleCell RNA sequencing and LEO Pharma’s global leadership in serving 90 million patients annually in medical dermatology to enhance understanding and treatment of skin diseases.
- This initiative reinforces LEO Pharma's commitment to unlock external innovation and drive standard of care improvement.
Ballerup, Denmark, 14 April 2025 – LEO Pharma and the Parker Institute at Copenhagen University Hospital have formed an academic partnership to advance research and innovation in medical dermatology. This collaboration aims to produce high-quality research that enhances disease understanding and benefits patients. Furthermore, it aims to discover molecules that could potentially be integrated into broader pharmaceutical research and development efforts.
“We are proud to partner with the Parker Institute in LEO Pharma’s first academic collaboration of this kind, strengthening ties to the academic world to foster innovative research”, said Dr. Jacob Pontoppidan Thyssen, Chief Scientific Officer & Executive Vice President at LEO Pharma. “While breakthroughs in skin science have improved treatment options, over 1000 skin diseases still lack effective treatments. This partnership is an important step in addressing these unmet needs. By combining our expertise, we aim to positively impact patients worldwide."
The Parker Institute excels in trial design and clinical testing across all phases, from early to late stages, and their expertise spans all forms of analysis. LEO Pharma aims to leverage the Parker Institute’s translational expertise to better understand immunophenotyping and how these insights apply to skin diseases. The Parker Institute’s proficiency in target evaluation and disease understanding will add significantly to LEO Pharma's research efforts.
Additionally, the Parker Institute's expertise in artificial intelligence (AI) and SingleCell RNA sequencing helps to understand how individual cells behave within the immune system. This advanced method, using AI, allows for a more detailed examination of single-cell data, giving a clearer understanding of how skin diseases work.
Dr. Lars Erik Kristensen, Vice President, Head of External Innovation at LEO Pharma, said, "Having spent several years at the Parker Institute prior to joining LEO Pharma, I have witnessed the dedication and expertise in their research efforts. By partnering with the Parker Institute, we see potential for unlocking new insights and strengthen our ability to advance the standard of care within medical dermatology. Earlier this year, LEO Pharma announced a collaboration with DEBRA Research, and this new partnership with the Parker Institute further reinforces our commitment to also leverage external innovation and use the world as our lab. By joining forces with such a recognized partner, we aim to advance our understanding of skin diseases, improve patient care, and potentially discover molecules that may be involved in wider pharmaceutical research and development initiatives later on."
Henning Bliddal, Head of the Parker Institute, added, "We are thrilled to collaborate with LEO Pharma, a global leader in medical dermatology. We have a shared commitment to advancing medical research and ultimately improving the lives of people suffering from skin diseases such as psoriasis and psoriatic arthritis, making LEO Pharma a strong partner for us.”
The partnership between LEO Pharma and the Parker Institute is a 3-year agreement.
Kontakter
For further information please contact:
Media: Jeppe Ilkjær, Head of Media Relations, LEO Pharma, mobile +45 3050 2014
Billeder
About Parker Institute
The Parker Institute is part of Copenhagen University Hospital at Bispebjerg and Frederiksberg. The Parker Institute strives, through research with focus on locomotory and related disorders, to improve the status of health in the population via prevention at all levels, increasing knowledge of disease mechanisms and diagnostics, and by creating evidence-based treatments. The activities include observations and register based research, analysis of literature, and diagnostic studies of patient-reported outcome measures, clinical tests, imaging with ultrasound and MRI, and biomechanical evaluation, as well as randomised clinical and population interventions. The Institute participates in creation of evidence-based prevention and medicine and in the development of new treatment strategies. The staff counts a broad range of health professionals and scientists, all dedicated to research into clinical advances for patients and disease prevention for the population. For more information, visit www.parker.dk.
About LEO Pharma
LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma submits adolescent label expansion application for Anzupgo® to EMA15.12.2025 09:00:00 CET | Pressemeddelelse
LEO Pharma has submitted a label expansion application to EMA to expand Anzupgo® (delgocitinib) cream to adolescent patients (12–17 years) with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate – the application has been accepted for review. The application is supported by results from DELTA TEEN, a phase 3 trial investigating efficacy and safety of Anzupgo® in adolescents with moderate to severe chronic hand eczema (CHE).1 The label expansion submission for adolescent patients demonstrates LEO Pharma's commitment to investigating use within relevant sub-populations where treatments can help make a fundamental difference for patients with skin diseases.
LEO Pharma Announces Positive Topline 32-Week Key Results in ADHAND Trial17.11.2025 09:00:00 CET | Pressemeddelelse
The ADHAND trial evaluates the efficacy and safety of tralokinumab in adult patients living with atopic dermatitis with moderate-to-severe hand involvement,1 a high burden, high unmet need population.2 At Week 16, tralokinumab showed statistically significant improvement compared to placebo in all primary and key secondary endpoints such as clear or almost clear skin, itch and pain.3 The 32-week results of the ADHAND trial builds on the positive findings observed at Week 16.
LEO Pharma delivers 8% revenue growth at CER in 9M 2025 and updates full-year outlook6.11.2025 09:00:00 CET | Pressemeddelelse
Ballerup, Denmark, 6 November, 2025 - In the first nine months of 2025, LEO Pharma continued its robust revenue growth, with significantly improved profitability and free cash flow. As expected, growth accelerated in the third quarter, with the global rollout of Anzupgo® gaining further momentum after its September launch in the U.S. The 2025 financial outlook is updated to reflect the addition of Spevigo® to the portfolio, reinforcing LEO Pharma’s commitment to advancing innovation and expanding access to care. Highlights LEO Pharma’s revenue increased by 7% to DKK 10,064 million, and by 8% at constant exchange rates (CER), entirely driven by organic growth. The revenue growth was led by North America (+27% at CER), with Europe (+2% at CER) and Rest of World (+6% at CER) also contributing to the overall growth. Revenue from the Dermatology portfolio grew by 9% (CER), driven by the Strategic brands Adtralza®/Adbry® and Anzupgo®, which combined had a revenue increase of 41% (CER), in ad
LEO Pharma announces NICE recommendation of reimbursement in England and Wales5.11.2025 12:00:00 CET | Pressemeddelelse
The National Institute for Health and Care Excellence (NICE) has recommended the first-and-only topical treatment for adults in the United Kingdom specifically approved for moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate.1 The Technology Appraisal Guidance (TAG) means NHS organisations in England and Wales must now make Anzupgo® ▼(delgocitinib) cream available for healthcare professionals to prescribe. CHE affects around 4.4 million2,3 adults in the UK, with 70% of those with severe forms reporting problems performing everyday activities4, and 58% saying it interferes with their ability to work5.
LEO Pharma strengthens leadership in medical dermatology with the appointment of Sophie Lamle as Chief Development Officer3.11.2025 12:00:00 CET | Pressemeddelelse
Sophie Lamle brings over 20 years of experience in the pharmaceutical industry, leading innovation, clinical development, and strategic transformation. Her appointment will further strengthen LEO Pharma’s Search & Develop innovation model, unlocking value with a focus on differentiated assets.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum